Please login to the form below
Aeras
This page shows the latest Aeras news and features for those working in and with pharma, biotech and healthcare.
Tuberculosis: treatment and prevention
Aeras and GlaxoSmithKline (GSK) Biologicals have entered into a public-private partnership to develop GSK's tuberculosis vaccine candidate, GSK 692342. ... incentives. The Bill and Melinda Gates Foundation recently gifted $280m to the Aeras Global TB
Latest news
-
GSK boost vaccines capabilities with €250m Okairos purchase
Okairos, which has received investment from BioMedInvest, Boehringer Ingelheim, LSP, Novartis and Versant Ventures, has already received attention for its novel chimpanzee-based platform, including a collaboration with Aeras and the
-
TB vaccine disappoints, but others in the pipeline
Helen McShane of the University of Oxford in the UK. The trial was sponsored by non-profit vaccines company Aeras, the Wellcome Trust and the Oxford-Emergent Tuberculosis Consortium (OETC), a ... Meanwhile, there are several other TB vaccines in the
-
Dutch invest in TB vaccines
The funding has also made a valuable contribution to Crucell and Aeras' AdVac-based TB vaccine. ... of limited investment - which Aeras TB Global president and CEO, Dr Jerald Sadoff, hopes will be further remedied by the recent Dutch input.
-
Tackling the TB threat
Among these is a recombinant adenoviral vector TB vaccine, currently in phase I trials, being developed by Crucell and Aeras Global TB Vaccine Foundation, an international non-profit academia-industry partnership. ... Further along the pipeline, in phase
More from news
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Biotech profile: Tom Evans, CEO, Vaccitech.
In September 2010 he joined Aeras, a non-profit Product Development Partnership with a mission to develop global tuberculosis vaccines, as the Chief Scientific Officer, and became CEO in February 2013.
-
Interview: Charles Mgone, EDCTP
But it doesn't stop the contagious form acquired by adults. So we are working with Emergent BioSolutions and Aeras, a non-profit product developer, as well as institutions in the
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
GlycoVaxyn appoints Gerd Zettlmeissl as chairman
He currently serves on the boards of several biotechnology companies including Aeras, an organisation dedicated to the development of tuberculosis vaccines.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- BMS will not launch cancer drug Opdualag in Germany due to pricing pressures
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- LEO Pharma enters clinical trial partnership with ICON
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Roche’s Polivy backed by FDA Advisory Committee for lymphoma therapy
- How to create content for health professionals
- Sanofi to cut US insulin prices by up to 78% in January 2024
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- 2023 PM Society Awards – winners announced
- Next congress, please: making the most of virtual pharmaceutical congresses
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- A relentless commitment to neuroscience
- Trust me, I’m from pharma
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
PMHub
Four Health
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...
Latest intelligence
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- By offering patients knowledge, skills and confidence, they empower patients to be more actively involved in their health. Holistic support can help tackle adherence, mental health or anything else patients...
- THE EVOLVING ROLE OF PROCUREMENT?
- Procurement is evolving to reinforce its position as a strategic enabler of company growth. How can agency partners organisations to realise this?...
